Table 1 Baseline characteristics of the study population in two groups of eGDR
|  | Total population (n = 1510) | Lower eGDR (≤ 7.76; n = 754) | Higher eGDR (> 7.76; n = 756) | P value |
|---|---|---|---|---|
Age, years | 59.67 ± 9.27 | 60.14 ± 9.20 | 59.20 ± 9.31 | 0.048 |
Sex, male, n (%) | 1113 (73.7) | 570 (75.6) | 543 (71.8) | 0.096 |
BMI, kg/m2 | 25.78 ± 3.15 | 27.03 ± 2.88 | 24.53 ± 2.90 |  < 0.001 |
WC, cm | 89.60 ± 11.96 | 94.48 ± 10.67 | 84.75 ± 11.17 |  < 0.001 |
Heart rate, bpm | 68.62 ± 9.96 | 68.93 ± 10.18 | 68.31 ± 9.74 | 0.233 |
SBP, mmHg | 129.48 ± 16.02 | 133.03 ± 16.44 | 125.94 ± 14.79 |  < 0.001 |
DBP, mmHg | 77.09 ± 9.57 | 78.70 ± 9.77 | 75.48 ± 9.10 |  < 0.001 |
Smoking history, n (%) | 892 (59.1) | 460 (61.0) | 432 (57.1) | 0.127 |
Drinking history, n (%) | 352 (23.3) | 179 (23.7) | 173 (22.9) | 0.694 |
Family history of CAD, n (%) | 143 (9.5) | 70 (9.3) | 73 (9.7) | 0.805 |
Medical history, n (%) | ||||
 Hypertension | 863 (57.2) | 745 (98.8) | 118 (15.6) |  < 0.001 |
 Hyperlipidemia | 1276 (84.5) | 647 (85.8) | 629 (83.2) | 0.161 |
 Previous MI | 309 (20.5) | 150 (19.9) | 159 (21.0) | 0.584 |
 Previous PCI | 231 (15.3) | 114 (15.1) | 117 (15.5) | 0.847 |
 Previous stroke | 155 (10.3) | 102 (13.5) | 53 (7.0) |  < 0.001 |
 Previous PAD | 51 (3.4) | 29 (3.8) | 22 (2.9) | 0.314 |
Clinical diagnosis, n (%) | Â | Â | Â | 0.962 |
 UA | 1271 (84.2) | 635 (84.2) | 636 (84.1) |  |
 NSTEMI | 239 (15.8) | 119 (15.8) | 120 (15.9) |  |
Laboratory examinations | ||||
 TG, mmol/L | 1.46 (1.04, 2.03) | 1.54 (1.10, 2.11) | 1.35 (0.99, 1.93) |  < 0.001 |
 TC, mmol/L | 4.20 ± 1.03 | 4.17 ± 1.00 | 4.24 ± 1.06 | 0.190 |
 LDL-C, mmol/L | 2.55 ± 0.88 | 2.53 ± 0.86 | 2.58 ± 0.90 | 0.351 |
 HDL-C, mmol/L | 1.00 ± 0.24 | 0.98 ± 0.22 | 1.02 ± 0.25 |  < 0.001 |
 hs-CRP, mg/L | 1.16 (0.52, 2.82) | 1.32 (0.61, 3.14) | 0.97 (0.45, 2.55) |  < 0.001 |
 Creatinine, μmol/L | 77.19 ± 16.18 | 79.52 ± 16.75 | 74.87 ± 15.25 |  < 0.001 |
 eGFR, mL/(min × 1.73m2) | 92.00 ± 18.85 | 89.43 ± 18.72 | 94.56 ± 18.64 |  < 0.001 |
 Uric acid, μmol/L | 353.47 ± 82.03 | 366.25 ± 81.91 | 340.72 ± 80.19 |  < 0.001 |
 FBG, mmol/L | 5.32 ± 0.60 | 5.37 ± 0.61 | 5.27 ± 0.59 | 0.001 |
 HbA1c, % | 5.64 ± 0.39 | 5.70 ± 0.38 | 5.59 ± 0.39 |  < 0.001 |
 LVEF, % | 64.03 ± 6.78 | 64.12 ± 6.47 | 63.94 ± 7.09 | 0.590 |
Medication at admission, n (%) | ||||
 ACEI/ARB | 304 (20.1) | 242 (32.1) | 62 (8.2) |  < 0.001 |
 DAPT | 440 (29.1) | 224 (29.7) | 216 (28.6) | 0.627 |
 Aspirin | 793 (52.5) | 403 (53.4) | 390 (51.6) | 0.469 |
 P2Y12 inhibitors | 473 (31.3) | 238 (31.6) | 235 (31.1) | 0.841 |
 β-Blocker | 339 (22.5) | 195 (25.9) | 144 (19.0) | 0.002 |
 Statins | 474 (31.4) | 234 (31.0) | 240 (31.7) | 0.766 |
Medication at discharge, n (%) | ||||
 ACEI/ARB | 984 (65.2) | 732 (97.1) | 252 (33.3) |  < 0.001 |
 DAPT | 1510 (100.0) | 754 (100.0) | 756 (100.0) | - |
 Aspirin | 1510 (100.0) | 754 (100.0) | 756 (100.0) | - |
 P2Y12 inhibitors | 1510 (100.0) | 754 (100.0) | 756 (100.0) | - |
 β-Blocker | 1351 (89.5) | 688 (91.2) | 663 (87.7) | 0.025 |
 Statins | 1469 (97.3) | 734 (97.3) | 735 (97.2) | 0.881 |
Angiographic data, n (%) | ||||
 LM lesion | 59 (3.9) | 29 (3.8) | 30 (4.0) | 0.903 |
 Bifurcation | 291 (19.3) | 140 (18.6) | 151 (20.0) | 0.489 |
 Multi-vessel lesion | 905 (59.9) | 498 (66.0) | 407 (53.8) |  < 0.001 |
 In-stent restenosis | 67 (4.4) | 33 (4.4) | 34 (4.5) | 0.909 |
 Chronic total occlusion lesion | 182 (12.1) | 103 (13.7) | 79 (10.4) | 0.055 |
 SYNTAX score | 9.86 ± 5.25 | 10.38 ± 5.32 | 9.34 ± 5.13 |  < 0.001 |
 Gensini score | 30.97 ± 14.39 | 31.14 ± 14.30 | 30.79 ± 14.50 | 0.639 |
Procedural information | ||||
 Target vessel territory, n (%) | ||||
  LM | 35 (2.3) | 15 (2.0) | 20 (2.6) | 0.397 |
  LAD | 993 (65.8) | 479 (63.5) | 514 (68.0) | 0.068 |
  LCX | 469 (31.1) | 261 (34.6) | 208 (27.5) | 0.003 |
  RCA | 580 (38.4) | 313 (41.5) | 267 (35.3) | 0.013 |
Complete revascularization, n (%) | 949 (62.8) | 453 (60.1) | 496 (65.6) | 0.026 |
 Number of DES | 2.00 (1.00, 2.00) | 2.00 (1.00, 3.00) | 1.00 (1.00, 2.00) | 0.002 |